This study is a registry, meaning it collects information from people with pulmonary hypertension (high blood pressure in the lungs) associated with interstitial lung disease (PH-ILD) and interstitial lung disease (ILD). It aims to better understand how these conditions progress and how treatments like Tyvaso/Tyvaso DPI affect patients in real-world settings. Researchers will gather information on patient characteristics, treatments, and health outcomes over time. You may be able to join if you are an adult aged 18 or older with a diagnosis of fibrotic ILD. The main goal is to describe the characteristics of patients at the beginning of the study. The study is currently unclear on its recruitment status.

Study design

This is an observational study that will enroll approximately 900 participants into four different groups based on their treatment with Tyvaso/Tyvaso DPI or risk of PH.

What's involved

You would complete assessments at 3 months, then at 6- and 12-month intervals for up to 5 years. These assessments may involve providing information that is not already part of your standard medical care.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for up to 5 years after joining the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.